Literature DB >> 2853775

Plasma concentration of alpha-hANP and renal responses to alpha-hANP infusion in patients with congestive heart failure and those with chronic renal failure.

Y Hirata1, M Ishii, H Matsuoka, T Sugimoto, M Iizuka, T Serizawa, O Kohmoto, T Sugimoto, A Miyata, K Kangawa.   

Abstract

To study the role of alpha-human atrial natriuretic polypeptide (alpha-hANP) in body fluid regulation, we measured the plasma concentration of alpha-hANP and renal function in 9 patients with congestive heart failure (CHF), 10 with chronic renal failure (CRF) and 8 normotensives (NT) before and during alpha-hANP infusion at 0.025 microgram/kg.min. The plasma concentration of alpha-hANP was significantly higher in the CHFs and CRFs than in the NTs (319, 168 and 72 pg/ml, respectively). Alpha-hANP infusion decreased mean blood pressure in a similar manner in the 3 groups (-5%, p less than 0.01 each). Increases in urinary sodium excretion and glomerular filtration rate during alpha-hANP infusion, however, were greater in the CHFs and CRFs than in the NTs. Furthermore, the higher the preinfusion level of renal vascular resistance (RVR), the greater was the reduction in RVR by alpha-hANP (r = -0.80, p less than 0.001). The metabolic clearance rate (MCR) of alpha-hANP was significantly smaller in the CHFs and CRFs than in the NTs (38, 35 and 67 ml/min.kg, respectively). These results suggest that the renal vasodilatory actions of alpha-hANP seem to be enhanced in patients with increased RVR and that the elevation of the basal plasma concentration of alpha-hANP in CHFs and CRFs may be in part due to the low MCR.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853775     DOI: 10.1253/jcj.52.1459

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  1 in total

1.  Pharmacokinetics and effects of atrial natriuretic factor during hypothermic cardiopulmonary bypass.

Authors:  M Hynynen; K T Olkkola; R Palojoki; I Tikkanen; F Fyhrquist
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.